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ABSTRACT 
 
Developing Methods for Antagonizing TNF-α and IL-1β in the Central 
Nervous System 
 
Elizabeth Ashley Hardin 
Department of Psychology 
Texas A&M University 
 
Fellows Advisor: Dr. Mary Meagher 
Department of Psychology 
 
 
Stressful life events have been linked to the onset, susceptibility, and even 
progression of neurodegenerative diseases such as multiple sclerosis (MS).  
Theiler’s murine encephalomyelitis virus (TMEV) infection, a well-characterized 
animal model of MS, is used in our laboratory to investigate the interaction 
between social stressors and disease development.  Social disruption (SDR), a 
model of social stress used in our laboratory, appears to worsen Theiler’s virus 
infection through excessive inflammation.  Prior findings from our laboratory 
indicate that pro-inflammatory cytokine IL-6 is partially mediating the negative 
effects of SDR in the development of Theiler’s virus infection.  In order to 
examine the role of other pro-inflammatory cytokines, our objective was to 
develop techniques to block the cytokines TNF-α and IL-1β.  Prior studies have 
indicated stress-induced release of these cytokines (TNF-α and IL-1β) may 
mediate the adverse effects of disease development in subsequent immune 
challenges.  Balb/cJ mice were implanted with a permanent indwelling cannula in 
iv 
the left lateral ventricle of the brain and allowed to recover for one week prior to 
manipulations.  Once the animals recovered from cannulation surgery, 
neutralizing antibody to TNF-α or IL-1β was administered during the period of 
SDR.  Antibody-SDR treatments continued for one week.   Mice were sacrificed 
the morning following last day of SDR.  Brains and sera were collected to 
measure TNF-α or IL-1β levels.  Spleens were harvested to examine the 
development of glucocorticoid resistance (GCR), a hallmark of SDR, in the TNF-
α study only.  The ELISA assay was not sensitive enough to the tissue levels of 
TNF-α, therefore successful antagonism was undetectable.  In contrast, IL-1β 
was elevated during SDR; however, it appears that the antibody was only 
partially effective at the dose administered.  The GCR assay indicated that 
resistance occurred in antibody treated and control mice in the TNF-α study, 
signifying that antibody treatment does not interfere with the development of 
normal social stress effects.  Future studies are necessary to identify an effective 
blocking dose for the neutralizing antibody to IL-1β.  In addition, we also need to 
develop alternative assays, such as RT-PCR or an RNase protection assay, that 
are sensitive to the levels of TNF-α associated with SDR.
v 
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I INTRODUCTION 
Numerous studies have established that chronic stress suppresses the ability 
of the immune system to respond to challenge and, thereby, increases 
vulnerability to opportunistic infection (Ader et al., 1991; Kiecolt-Glaser et al., 
1995).  Prior research also indicates that the onset, development, and even 
severity of neurodegenerative diseases are stress-related (Rosch, 1979; McGeer 
& McGeer, 1995; Njenga et al., 1997; Busciglio et al., 1998; Floyd, 1999; Nguyen 
et al., 2002).  Additionally, stressful life events and poor social support appear to 
play a role in the onset and progression of autoimmune diseases, such as 
rheumatoid arthritis (Curtis et al., 2005; Straub et al., 2005; Veldhuijzen van 
Zanten et al., 2005) and multiple sclerosis (MS) (Ackerman et al., 1998; Mohr et 
al., 2000).  Our laboratory has been using Theiler’s murine encephalomyelitis 
virus (TMEV) infection, an animal model of MS, to better understand the 
mechanisms that underlie the effects of stress in neurodegenerative diseases, 
such as MS.  Developing techniques to block cytokines will aid in our ability to 
determine these mechanisms. 
Theiler’s virus infection is a well-characterized animal model of MS that allows 
us to investigate central nervous system (CNS) inflammation as it relates to 
stress (Lipton, 1975; Oleszak et al., 2004).  Theiler’s virus infection induces a 
biphasic disease in susceptible strains of mice, such as the Balb/cJ strain used in 
these experiments.  The early acute phase of the disease is primarily CNS 
inflammatory and is characterized by the infection of central neurons and glia 
(astrocytes, microglia, and oligodendrocytes).  The chronic phase, which serves 
  2  
 
 
as a model for MS, is primarily neuroinflammatory and demyelinating.  In order to 
develop the chronic phase of Theiler’s virus infection, the virus must remain in 
the CNS beyond the resolution of the acute phase (Aubert et al., 1987; Oleszak 
et al., 2004).  The chronic phase is characterized by massive mononuclear 
inflammatory infiltration, demyelinating lesions, and behavioral manifestations 
similar to MS (Lipton, 1975; Njenga et al., 1997; Oleszak et al., 2004).  
Previous studies in our laboratory investigated the impact of stress, restraint 
(RST) or social disruption (SDR), on the disease course of Theiler’s virus 
infection.  RST involves restraining mice in plastic syringes for a designated 
period of time (Sheridan et al., 1991; Campbell et al., 2001), whereas SDR 
involves introducing an intruder mouse into a cage of resident mice for a 
designated period of time (Avitsur et al., 2001; Stark et al., 2001).  These studies 
have demonstrated that stress exacerbates disease development in Theiler’s 
virus infection in both the acute and chronic phases of the disease (Johnson et 
al., 2004; Johnson et al., in press; Sieve et al., 2004).   
RST led to decreased CNS inflammation during acute infection, and 
increased behavioral manifestations of encephalitis, mortality rates, and viral 
titers (Campbell et al., 2001; Sieve et al., 2004).  The association between RST 
and decreased inflammation is further supported by studies using LPS (a 
bacterial endotoxin) induced endotoxemia, which also found that RST led to 
decreased inflammation (Padgett et al., 1998; Konstantinos et al., 2001; Quan et 
al., 2001).   In contrast to RST, SDR leads to an increase in systemic 
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inflammation in mice exposed to LPS (Quan et al., 2001), as well as central 
inflammation in Theiler’s virus infection (Johnson et al., 2004). 
Although RST and SDR cause divergent effects on inflammation, both 
stressors lead to exacerbations of Theiler’s virus infection.  Mice exposed to SDR 
developed a more severe disease course, greater inflammation, and were unable 
to clear Theiler’s virus from the CNS over time (Johnson et al., 2004).  As 
mentioned previously, the inability to clear the virus over time is necessary in 
developing chronic phase illness.  SDR also led to the development of 
glucocorticoid resistance (GCR), or the failure of immune cells to down-regulate 
in the presence of glucocorticoids (GC), whereas RST typically does not lead to 
GCR (Johnson et al., 2004; Avitsur et al., 2002; Quan et al., 2001).   
GCR develops in the macrophages of the spleen due to SDR, and leads to a 
dysregulation of pro-inflammatory cytokine function (Avitsur et al., 2002).  One 
function of corticosteroids is to mediate the innate immune response by 
suppressing the production and proliferation of pro-inflammatory cytokines (IL-6, 
IL-1β, and TNF-α) and enhancing the action of anti-inflammatory cytokines (IL-10 
and IL-4) (Angeli et al., 1999; Lew et al., 1988; Franchimont et al., 1999; Hart et 
al., 1990).  However, in SDR mice, increased inflammation and decreased viral 
clearance are found even though corticosteroid levels are elevated (Johnson et 
al., 2004).  These findings imply that the development of GCR may exacerbate 
the inflammatory response due to an immune challenge.  The development of 
GCR (and commensurate dysregulation of pro-inflammatory cytokines) in SDR 
mice may then be mediating the differential development of inflammation when 
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comparing RST and SDR (Quan et al., 2001; Johnson et al., 2004; Sieve et al., 
2004). 
However, pro-inflammatory cytokines may also mediate the development of 
GCR.  For example, elevated levels of IL-6 are associated with an increase in the 
expression of the beta subtype of the GC receptor (and down-regulation of the 
alpha subtype receptor).  The GC receptor subtype beta has been associated 
with the development of GCR (Necela et al., 2004).  Thus, elevated pro-
inflammatory cytokines may be related to the development of GCR, while GCR 
also results in the production of elevated pro-inflammatory cytokines.  The 
exacerbated inflammatory response associated with the development of GCR 
may then mediate previously noted impaired clearance of the virus, and other 
disease exacerbations (Johnson et al., 2004).  
The SDR-induced exacerbated inflammatory response with Theiler’s virus 
infection is not only associated with high circulating levels of corticosteroids and 
GCR (Quan et al., 2001; Johnson et al., 2004), but also elevated cytokine levels 
(Johnson et al., in press).  Others have shown that elevated levels of pro-
inflammatory cytokines are associated with an activation of the hypothalamic-
pituitary-adrenal (HPA) axis and the sympathetic nervous system in response to 
stress (Watkins et al., 1998).  Activation of the HPA-axis ultimately results in the 
release of GC from the adrenal glands, and the sympathetic nervous system 
releases catecholamines (norepinephrine and epinephrine) that control the 
activity of various immune organs such as the spleen and thymus (Felten et al., 
1998; Watkins et al., 1998).  
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Cytokines released in the brain and in the periphery serve to mediate the 
development of inflammatory reactions to stress or immune challenges (Watkins 
et al., 1998).  Cytokine mediated responses to stress are very similar to those 
seen with an immune challenge alone, such as viral infection or exposure to LPS 
(Dantzer et al., 1999; Watkins et al., 1998).  For example, cytokines alone have 
been found to cause weight loss, anorexia, decreased motor activity, 
hypersomnia, reduced interest in social activity, and anhedonia (or the loss of 
interest in normally pleasurable activities) (Barak, 2002a, 2002b; Pollack et al., 
2000).  Of interest to the current studies, the levels of pro-inflammatory cytokines 
(IL-6, IL-1β and TNF-α) are elevated in both the acute phase of Theiler’s virus 
infection (for a review see Oleszak et al., 2004), and separately in SDR (Avitsur 
et al., 2005; Stark et al., 2002).  
Because there is a correlation between stress-induced pro-inflammatory 
cytokine levels, the development of GCR, and worsening of Theiler’s virus 
disease development, our laboratory investigated the effect of blocking IL-6 on 
the development of GCR.  Based on the relationship between GCR and IL-6 
(Necela et al., 2004), it was postulated that IL-6 may induce GCR, and that 
blocking IL-6 would restore a normal response to GC in mice.  Then, 
normalization of GC sensitivity would lead to a less severe disease course.  
Antagonism of IL-6 did not affect the development of GCR.  However, the 
negative effects of SDR-induced Theiler’s virus infection were reversed (Johnson 
et al., in submission).  Therefore, IL-6 seems to be acting through a mechanism 
independent of this phenomenon.  The idea that stress-mediated inflammation of 
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the CNS and exacerbation of disease course may be caused by cytokine 
activation in response to stress is intriguing, and is the focus of ongoing work in 
our laboratory. 
The present studies seek to further examine the immunological mechanisms 
whereby stress has an effect on the disease course of subsequent immune 
challenges, and is the first of several subsequent studies.  In order to begin to 
elucidate the role of cytokines other than IL-6, we must first determine methods 
to block their action, as well as measure the effects of such antagonism.  This 
study is necessary in that it serves to evaluate whether or not SDR results in 
subsequent increases in pro-inflammatory cytokines TNF-α or IL-1β, and whether 
or not techniques used previously in our laboratory are effective in blocking these 
elevated levels.  The current studies will effectively lay the groundwork for future 
studies to investigate the action of these cytokines in mediating the adverse 
effects of stress on Theiler’s virus infection. 
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II GENERAL METHODS 
1.  Animals 
Male Balb/cJ mice were acquired from Jackson Labs (Bar Harbor, ME).  
Mice arrived from the breeder at post-natal day (pnd) 23 and were weighed and 
assigned to individual cages.  On pnd 24 mice were cannulated (see below).  
Following cannulation, mice continued to be individually housed for 48 h.  On pnd 
26, mice were placed in group-housing, 3/cage, counterbalanced by weight.  
Mice were maintained on a 12-h light/dark cycle (0500-h/ 1700-h) with ad libitum 
access to food and water, with the exception of the 2 h SDR sessions.   
Intruders for the SDR were retired male breeders, 6-to-8 mo of age, 
housed with sterilized females to increase territoriality and aggressive behavior.  
The intruders were selected based on latency to attack both peers and 
adolescents.  All intruders consistently attacked peers within 30 s and 
adolescents within 2 min on 3 separate occasions.  All animal care protocols 
were in accordance with NIH Guidelines for Care and Use of Laboratory Animals 
and were approved by the Texas A&M University Laboratory Animal Care and 
Use Committee (ULACC). 
2.  Cannulation surgery 
Mice were anesthetized with isoflurane gas (2-5%), heads shaved, eyes 
coated with petroleum jelly, and placed in a mouse adapted stereotaxic device 
fitted with a mouse nose cone (#51625, #51609, Stoelting, Wood Dale, IL).  The 
isoflurane delivery system was purchased from Vet Equip (#901806, Pleasanton, 
CA), and the gas recovery system was purchased from Surgivet (model AES, 
  8  
 
 
Waukesha, WI).   An incision was made longitudinally along the midline of the 
skull and the skull was exposed (hemostats were not needed).  The periosteum 
was removed with a sterile cotton swab, and 2% lidocaine was applied to the 
wound.  Bregma was located and noted.  Rostral-caudal leveling was 
accomplished by measuring the vertical position (z plane) of lambda and bregma 
and ensuring that they were equalized.  The skull was swabbed dry, and the 
cannulation hole was drilled at +1 mm lateral to bregma and -.4 mm rostral to 
bregma over the left lateral ventricle (based on Paxinos & Franklin).  Guide 
cannulas (33g), purchased from Plastics One (Roanoke, VA, C315GS-2/SPC), 
were pre-cut to a depth of 1.75 mm, and implanted and secured with 
cyanoacrylic gel according the manufacturer’s suggestion.  Mice were then 
wrapped with bubble wrap to aid in insulation to combat hypothermia induced by 
anesthesia, and placed back in the home cage that was warmed over a heating 
pad.  Mice were monitored until fully awake and ambulatory.  Once ambulatory, 
bubble wrap was removed, and mice were returned to the animal colony.  For 
pain control post-surgery, mice were provided with water treated with Tylenol 
(325 mg/2000 mL).  To aid in recovery, mice were also provided with food 
softened with the Tylenol treated water in the cage.  Mice were allowed to 
recover approximately 6 d prior to any further procedures.   
3.  Social disruption (SDR) stress 
For the stressed mice, intruders were introduced into the cage of resident 
mice at dark cycle onset (1700 h) for a period of 2 h for a total of 6 SDR sessions 
the week prior to infection, beginning on pnd 30.  SDR occurred for 3 consecutive 
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sessions, then 1 night off, followed by 3 additional consecutive sessions (Avitsur 
et al., 2001; Stark et al., 2001), in a separate procedure room.  SDR sessions 
were monitored to ensure that the intruder attacked the residents and that the 
residents demonstrated submissive behaviors.  Intruders that did not attack 
within 10 min of session initiation were replaced, and the session continued for 
the remaining 2 h. 
4.  Sacrifice 
Mice were sacrificed the morning following the last session of SDR.  Each 
mouse was overdosed with ketamine (100mg/kg)/xylazine (5 mg/kg), and bled 
from the brachial artery.  Spleen, brain, and spinal cord were harvested 
appropriately and weighed.  Brains and spinal cords were flash frozen in liquid 
nitrogen, and stored at -80 ºC until an ELISA was performed. 
5.  Corticosteroid sensitivity assay 
On the sacrifice day, spleens were harvested to determine sensitivity of 
splenocytes to GC regulation (as per Stark et al., 2001).  Briefly, spleens were 
placed in ice-cold Hank’s balanced salt solution (HBSS), and mashed to obtain a 
single cell solution.  Red blood cells were then lysed (red blood cell lysis, Sigma, 
St. Louis, MO), followed by a wash of HBSS+10% heat inactivated fetal bovine 
serum (FBS-HI, Equitech, Kerrville, TX).  Viable cells were then counted using 
trypan blue dye exclusion and re-suspended at 2.5 X 106 cells/mL in 
supplemented RPMI (Sigma)+10% FBS-HI (supplementation: 75% sodium 
bicarbonate, 10 mM Hepes buffer, 100 U/mL penicillin, 100 μg/mL streptomycin 
sulfate, 1.5 mM l-glutamine, and .00035% 2-mercaptoethanol).  LPS (Sigma # 
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L6529) in 2% ethanol was added at a concentration of 1 μg/mL for mitogen 
stimulation.  GC resistance was tested by exposing aliquots of each suspension 
to dilutions of corticosteroid (0-5 μM, Sigma, St. Louis, MO, #C2505) dissolved in 
2% ethanol and supplemented RPMI.  Cell suspensions were placed in triplicate 
in flat-bottomed 96-well micro-titer plates in 100 μL aliquots and incubated for 48-
72 h at 37°C and 5% CO2.  After incubation, the cell survival assay was 
performed. 
Cell proliferation was assessed following the manufacturer’s instructions 
with the CellTiter 96 Aqueous non-radioactive proliferation assay kit from 
Promega (Madison, WI).  Color changes were quantified by optical density 
readings at 490 nm from an EMAX ELISA plate reader (Molecular Devices, 
Sunnyvale, CA).  Mean optical density values for the 3 replications for each 
sample were used, and the percentage of the corticosteroid-exposed cells versus 
the LPS stimulated cells was determined for statistical analysis.  
6.  Statistical analyses 
Data are presented as mean + SEM.  Analysis of variance (ANOVA) was 
used to evaluate differences across SDR-antibody and SDR-vehicle conditions. 
These analyses were followed by post hoc mean comparisons using Duncan's 
New Multiple Range Test. 
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III EXPERIMENT 1: TNF-α 
1. Introduction 
Our laboratory has previously demonstrated that pro-inflammatory 
cytokine IL-6 is necessary in mediating the adverse effects of Theiler’s virus 
infection.  However, IL-6 alone is not sufficient in replicating the negative effects 
of SDR on the development of Theiler’s virus infection.  This indicates that pro-
inflammatory cytokine IL-6 is not solely responsible for the SDR-induced 
exacerbations of Theiler’s virus infection.  Theiler’s virus infection is not only 
associated with high transcript levels of pro-inflammatory cytokine IL-6, but also 
TNF-α, in susceptible strains of mice (Oleszak et al., 2004).  High levels of TNF-α 
are also associated with SDR and challenges to the immune system (Avitsur et 
al., 2005).  Therefore, based on previous experiments, TNF-α may play a 
significant role in the mechanism mediating the adverse effects of Theiler’s virus 
infection.  Before behavior and illness measures can be conducted, the 
successful blockage of TNF-α in the CNS must be verified.  This study 
investigated whether or not SDR elevated levels of pro-inflammatory cytokine 
TNF-α and, if so, whether these elevations could be antagonized using the 
neutralizing antibody technique.  Therefore, this study is necessary to begin 
further investigation into the role of other pro-inflammatory cytokines (TNF-α and 
IL-1β) in mediating the adverse effects of Theiler’s virus infection. 
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2.  Methods 
2.1 Procedure 
Upon arrival, mice were weighed and caged individually.  The next 
morning, cannulation surgeries occurred.  Mice were allowed to recover in 
individual housing for 2 d.  On pnd 27, mice were weighed again and assigned to 
cages in a counterbalanced manner, based on weight.  The Tylenol water was 
removed and plain water was added to each cage.  On pnd 30, antibody or 
vehicle was administered daily beginning at 1300 h, and then the stressed 
animals were administered SDR at from 1700-1900 h.  Mice were sacrificed the 
morning following the last session of SDR. 
2.2 Antibody to TNF-α 
Polyclonal antibody to mouse TNF-α was purchased from R&D Systems 
(AF-406-NA, Madison, WI).  To provide the stock solution, the original 100 μg 
was dissolved in 1 mL sterile PBS.  The stock solution was then further diluted by 
1:20 to result in a 5 ng/μL solution.   
2.3 Antibody administration 
The 5 ng/μL solution of neutralizing antibody was administered using a 25-
μL Hamilton syringe and a pump set to administer 60 μL/hour through a 36-g 
cannula (Plastics One, Roanoke, VA, C315IDC/SPC).  2 μL was then 
administered over 2 min, followed by a 30 s delay to prevent backwash of the 
solution before the cannula was removed.  The total dose per animal was then 
10 ng.  This dose was based on the 50% neutralizing dose information provided 
by the manufacturer.  Control animals were administered mouse immunoglobulin 
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(Ig, Santa Cruz Biotechnology, Inc #SC-2025) in the same volume of sterile 
saline as the vehicle, in order to account for generalized responses to proteins. 
2.4 Efficacy of antibody treatment in blocking TNF-α 
In order to assess the efficacy of the antibody dose in blocking TNF-α, 12 
mice were used.  These animals arrived from breeder, were cannulated, and 
underwent SDR as described in the general methods section.  A 1 (SDR) x 2 
(antibody, vehicle) was used.  At 1300 h daily, 4 h prior to SDR, antibody or 
vehicle administration occurred.  Following SDR/treatment sessions, all animals 
were sacrificed and spleens were harvested for GCR assessment, while brain 
tissue and sera were assessed for TNF-α levels, using an ELISA assay. 
2.5 TNF-α ELISA 
An ELISA for the TNF-α assay was purchased from R & D Systems (R & 
D Systems Madison, WI), and sera (frozen at -80°C between sacrifice and the 
time of the assay) was assessed according to the manufacturer’s instructions.  
Brain tissue was homogenized in 1 mL of Dulbecco’s Eagle Medium (Sigma) and 
flash frozen.  Tissue was stored at -80°C until the time of the assay.  Tissue was 
then thawed and centrifuged at 2000 rpm for 5 min.  50 μL of the supernatant per 
well was used to assess TNF-α levels in the brain. 
3. Results 
3.1 Arrival Body Weights 
 Mice were weighed upon arrival at pnd 23, prior to all experimental 
manipulations, and were counterbalanced and housed in groups of three.  Figure 
  14  
 
 
1A shows initial body weights across groups.  ANOVA was used to confirm that 
there were no group differences prior to manipulations, F(1,10) =.368, p>.05.  
3.2 Spleen Weights 
Spleens were harvested from mice immediately upon sacrifice and 
weighed.  Figure 1B shows spleen weights in the antibody and vehicle treatment 
groups.  ANOVA confirmed that there were no group differences in these 
animals, F(1,10) =.238, p>.05.  Splenomegaly is often associated with the 
development of GCR, and the spleen sizes found here (.077g) are somewhat 
higher than our laboratory typically finds in non-stressed animals (.069g). 
 3.3 GCR Assay 
 Figure 1C shows GCR development with IL-6 antibody treatment at day 7 
post infection, from a previous study in our laboratory (top panel, Johnson et al., 
in submission), and GCR from the current study (bottom panel).  The data from 
the previous study is included in order to illustrate both normal GC sensitivity 
(NON-AbTx, NON-VEH, and SDR-VEH groups) and GCR (SDR-AbTx).  The 
bottom panel of Figure 1C shows that SDR-antibody treated mice in the TNF-α 
experiment developed GCR (cell survival rates of 80% or greater, regardless of 
corticosteroid level).  ANOVA confirmed that no significant decrease in cell 
survival occurred over increasing corticosteroid level, F(4,32) =.139, p>.05.  
Therefore, as with antibody to IL-6, antibody treatment to TNF-α does not 
interfere with the development of GCR.
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Figure 1A.  Arrival body weights for TNF-α mice 
Mice arrived at pnd 23 and were weighed prior to all 
manipulations.  No significant differences were found across 
groups prior to surgery or social disruption (p>.05). 
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Figure 1B.  Spleen weights for TNF-α mice 
 
Spleens were harvested from mice immediately upon sacrifice and 
weighed.  GCR is often highly associated with enlarged spleens.  
There were no significant differences in spleen weights between 
antibody and vehicle treatment groups in TNF-α mice (p>.05).  
Therefore, antibody treatment did not interfere with the 
development of GCR.
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Figure 1C. Glucocorticoid resistance (GCR) with IL-6 (top graph) 
and TNF-α antibody (bottom graph) treatment 
 
GCR development with IL-6 antibody treatment at day 7 post 
infection is shown in the graph on the top.  Both SDR groups 
developed GCR prior to infection.  Non-SDR mice, in comparison 
with SDR mice, did not develop GCR, indicated by the low cell 
survival rate at increasing levels of corticosteroids.  SDR-VEH and 
SDR-AbTx mice both developed glucocorticoid resistance, 
indicating that the IL-6 antibody treatment did not interfere with 
this phenomenon.  The graph on the bottom shows that TNF-α 
antibody treatment in SDR-antibody mice does not interfere with 
the development of GCR
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3.4 Verification of antibody treatment 
In order to verify that TNF-α was elevated due to SDR in the current 
study, and that this elevation was blocked by the neutralizing antibody treatment, 
an ELISA for TNF-α was used to test both brains and sera.  The levels of TNF-α 
were not quantifiable, in either the brain or sera, using an ELISA.  Therefore, 
successful antagonism of TNF-α was not measurable. 
4. Discussion 
Previous studies in our laboratory investigating pro-inflammatory cytokine 
IL-6 indicated that SDR alone elevates cytokine levels, and that the neutralizing 
antibody treatment successfully blocked cytokine levels in both the brain and 
periphery (Johnson et al., in submission).  This study examined whether SDR 
elevated levels of TNF-α in the brain and periphery, and if so, whether or not 
these elevations could be antagonized using the neutralizing antibody technique.  
Splenomegaly and the development of GCR occurred in both antibody and 
vehicle groups in the TNF-α experiment, indicating successful application of 
SDR.  These findings also show that antibody treatment does not interfere with 
the development of GCR.  An ELISA conducted in this study indicated that levels 
of TNF-α were not quantifiable in either the CNS or the periphery in mice 
receiving either antibody or vehicle treatments.  Therefore, blockage of the 
cytokine was not able to be measured.  Before we are able to verify whether or 
not TNF-α can be successfully blocked in the CNS and periphery, and further 
investigate the role of this cytokine in the mechanisms mediating the adverse 
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effects on disease course development, more sensitive assays must be 
developed, such as RT-PCR or using blood plasma. 
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IV EXPERIMENT 2: IL-1β 
1. Introduction 
 The aim of the second study in this series was to develop methods to 
adequately block IL-1β, as well as to measure successful antagonism.  Similar to 
TNF-α, IL-1β is also dysregulated by GCR.  IL-1β plays an important role in the 
development of inflammatory responses, both due to stress and infection 
(Watkins et al., 1998).  Thus, the current study will use methods similar to 
Experiment 1 to develop antagonism methodologies for IL-1β. 
2.  Methods 
2.1 Procedure 
Upon arrival, mice were weighed and caged individually.  The next 
morning, cannulation surgeries occurred.  Mice were allowed to recover in 
individual housing for 2 d.  On pnd 27, mice were weighed again and assigned to 
cages in a counterbalanced manner, based on weight.  The Tylenol water was 
removed and plain water was added to each cage.  On pnd 30, antibody or 
vehicle was administered daily beginning at 1300 h, and then the stressed 
animals were administered SDR at from 1700-1900 h.  Mice were sacrificed the 
morning following the last session of SDR. 
2.2 Antibody to IL-1β 
Polyclonal antibody to mouse IL-1β was purchased from R&D Systems 
(AF-406-NA, Madison, WI).  To provide the stock solution, the original 100 μg 
was dissolved in 1 mL sterile PBS.  The stock solution was then further diluted by 
1:33 to result in a 2 ng/μL solution.  
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2.3 Antibody administration 
The 2 ng/μL solution of neutralizing antibody was administered using a 25-
μL Hamilton syringe and a pump set to administer 60 μL/hour through a 36-g 
cannula (Plastics One, Roanoke, VA, C315IDC/SPC).  2 μL was then 
administered over 2 min, followed by a 30 s delay to prevent backwash of the 
solution before the cannula was removed.  The total dose per animal was then 
10 ng.  This dose was based on the 50% neutralizing dose information provided 
by the manufacturer.  Control animals were administered mouse immunoglobulin 
(Ig, Santa Cruz Biotechnology, Inc #SC-2025) in the same volume of sterile 
saline as the vehicle, in order to account for generalized responses to proteins. 
2.4 Procedure 
In order to assess the efficacy of the antibody dose in blocking elevations 
in IL-1β, 12 mice were used.  These animals arrived from breeder, were 
cannulated, and underwent SDR as described in the general methods section.  A 
1 (SDR) x 2 (antibody, vehicle) was used.  At 1300 h daily, 4 h prior to SDR, 
antibody or vehicle administration occurred.  Following SDR/treatment sessions, 
all animals were sacrificed and brain tissue and sera were assessed for IL-1β 
levels, using an ELISA assay. 
2.5 IL-1β ELISA 
An ELISA for the IL-1β assay was purchased from R & D Systems (R & D 
Systems Madison, WI), and sera (frozen at -80°C between sacrifice and the time 
of the assay) was assessed according to the manufacturer’s instructions.  Brain 
tissue was homogenized in 1 mL of Dulbecco’s Eagle Medium (Sigma) and flash 
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frozen.  Tissue was stored at -80°C until the time of the assay.  Tissue was then 
thawed and centrifuged at 2000 rpm for 5 min.  50 μL of the supernatant per well 
was used to assess IL-1β levels in the brain. 
3. Results 
3.1 Arrival Body Weights 
 Mice were weighed upon arrival at pnd 23, prior to all experimental 
manipulations, and were counterbalanced and housed in groups of three.  Figure 
2A shows initial body weights across groups.  ANOVA was used to confirm that 
there were no group differences prior to manipulations, F(1,10) =.488, p>.05.  
3.2 Spleen Weights 
Spleens were harvested from mice immediately upon sacrifice and 
weighed. Figure 2B shows spleen weights in the antibody and vehicle treatment 
groups.  Splenomegaly is often associated with the development of GCR.  While 
animals receiving SDR alone had enlarged spleens compared to the animals 
receiving both SDR and antibodies, the difference was not significant.  ANOVA 
confirmed that there were no group differences in these animals, F(1,10) =2.747, 
p >.05.   
3.3 Verification of antibody treatment 
In order to verify that IL-1β was elevated due to SDR in the current study, 
and that this elevation was blocked by the neutralizing antibody treatment, an 
ELISA for IL-1β was used to test both brains and sera.  The data in Figure 2C 
indicate that levels of IL-1β were elevated due to SDR.  There was a marginal 
reduction effect only in the CNS of the IL-1β treated mice, F(1,9) =2.159, p =.1.  
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The IL-1β antibody treatment was not successful in blocking IL-1β in the 
periphery, F(1,9) =.63, p >.05. 
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Figure 2A.  Arrival body weights for IL-1β mice 
 
Mice arrived at pnd 23 and were weighed prior to all manipulations.  
These graphs demonstrate that there were no significant differences 
across groups prior to surgery or social disruption (p>.05). 
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Figure 2B.  Spleen weights for IL-1β mice 
 
Spleens were harvested from mice immediately upon sacrifice and 
weighed. GCR is often highly associated with enlarged spleens.  
There were no significant differences in spleen weights between 
antibody and vehicle treatment groups in IL-1β mice (p>.05).  
Therefore, antibody treatment did not interfere with the 
development of GCR. 
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Figure 2C.  Efficacy of neutralizing antibody treatment in IL-1β mice 
 
Mice were sacrificed the morning after their final SDR session, and 
brains and blood sera were collected to analyze the remaining levels 
of IL-1β using an ELISA.  A trend was seen in the reduction of IL-1β 
in the brain (p=.1). 
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4. Discussion 
This study examined whether IL-1β in the brain and periphery could be 
antagonized using the neutralizing antibody technique.  Splenomegaly was 
marginal in the vehicle group in the IL-1β experiment, indicating probable 
successful application of SDR.  Thus, the development of GCR is likely in these 
mice.  Although spleen weights were lower (not significantly) in the antibody 
treated animals, they probably also developed normal GCR, based on our 
previous findings.  Prior studies indicated that GCR developed in socially 
stressed mice receiving antibody to both IL-6 and TNF-α (Johnson et al., in 
submission).  Based on those prior studies, as well as time and money 
constraints, we did not perform a GCR assay on IL-1β mice.  Unlike the TNF-α 
study, an ELISA run on IL-1β mice revealed elevated levels of cytokine, and a 
marginal blocking effect was found in the CNS of antibody treated mice.  
However, the levels of IL-1β in the periphery were not altered.  This indicates that 
the blocking dose for IL-1β needs to be explored in future studies before the role 
of IL-1β in the mechanisms mediating the adverse effects of Theiler’s virus 
infection can be further investigated. 
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V SUMMARY AND CONCLUSIONS 
1. Summary 
These studies examined techniques used to antagonize pro-inflammatory 
cytokines TNF-α and IL-1β in the CNS.  Previous studies have indicated that the 
exacerbated effects of SDR on Theiler’s virus infection may be due to the action 
of pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α).  Our laboratory previously 
found IL-6 to be necessary, but not sufficient, in mediating the negative effects of 
Theiler’s virus infection (Johnson et al., in submission).  Therefore, IL-6 alone is 
not responsible for the exacerbations in motor impairment, excessive 
inflammation, and decreased viral clearance.  Therefore, this study began to 
investigate the roles of other pro-inflammatory cytokines, TNF-α and IL-1β. 
 The objective of the TNF-α study was to detect whether or not SDR 
elevated the levels of TNF-α in the CNS and periphery, and if so, whether these 
elevations could be successfully antagonized using techniques previously 
developed in our laboratory.  Neutralizing polyclonal antibody against murine 
TNF-α was administered through a permanent, chronic indwelling cannula 
implanted in the left lateral ventricle of the brain.  A GCR assay indicated that 
antibody treatment did not interfere with the development of GCR.  Levels of 
TNF-α were not quantifiable by an ELISA.  An assay that is more sensitive to 
levels of TNF-α, such as RT-PCR or an RNase protection assay, is needed.  
Because levels of TNF-α were not detected, successful antagonism of TNF-α is 
unknown. 
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 The objective of the IL-1β experiment was also to detect whether or not 
SDR altered the levels of IL-1β in the CNS and periphery, and whether these 
elevations could be successfully antagonized using techniques previously 
developed in our laboratory.  Neutralizing polyclonal antibody against murine IL-
1β was administered through a permanent, chronic indwelling cannula implanted 
in the left lateral ventricle of the brain.  An ELISA indicated that levels of IL-1β 
were elevated in the CNS and periphery.  Partial antagonism in the CNS of IL-1β 
was indicated by the low, however insignificant, p-value (p=.1).  Therefore, a 
dose response curve is needed in order to block the action of IL-1β, and begin 
investigating the role of IL-1β in mediating the adverse effects of Theiler’s virus 
infection. 
2. General Discussion and Conclusions 
These studies showed that the antagonism of pro-inflammatory cytokines 
TNF-α and IL-1β requires different techniques than those previously used in our 
laboratory to block the action of IL-6.  Previous studies in our laboratory have 
shown that SDR leads to exacerbations of Theiler’s virus infection including 
elevated motor impairment, elevated inflammation, and decreased viral 
clearance (Johnson et al., 2004; Johnson et al., in submission).  These studies 
also indicated that SDR led to the development of GCR.  As stated previously, 
GCR is the failure of immune cells to down-regulate in the presence of GC, and 
results in the dysregulation of pro-inflammatory cytokines.  Elevations in 
inflammation due to SDR may result in the exacerbation of acute Theiler’s virus 
infection. 
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Prior studies in our laboratory have indicated that antagonism of IL-6, 
using the methods previously described, led to the reversal of the adverse effects 
of Theiler’s virus infection (Johnson et al., in submission).  Antagonism of IL-6 
was found to reverse SDR-induced exacerbations of motor impairment, elevated 
inflammation, and decreased viral clearance (Johnson et al., 2004; Johnson et 
al., in submission).  Although IL-6 is necessary in mediating the adverse effects 
of Theiler’s virus infection, it is not sufficient in mimicking the effects of SDR 
alone.  Therefore, IL-6 is not the only mediator of the SDR-induced adverse 
effects of Theiler’s virus infection.  Thus, previously noted elevations in pro-
inflammatory cytokine IL-6 led to the hypothesis that other pro-inflammatory 
cytokines (IL-1β and TNF-α) may also be mediating the adverse effects of 
Theiler’s virus infection. 
This study was necessary in order to begin elucidating the roles of pro-
inflammatory cytokines TNF-α and IL-1β in mediating the adverse effects of 
Theiler’s virus infection due to stress.  Before beginning an expensive, time-
consuming study, our laboratory was interested in whether SDR alone elevated 
levels of pro-inflammatory cytokines TNF-α and IL-1β.  Our laboratory was also 
interested in whether these elevated levels of cytokines could be successfully 
antagonized by replicating the methodology used in the previous IL-6 study.  
Since previous studies in our laboratory have shown that cytokine levels of IL-6 
were elevated in SDR mice in comparison to control mice (Johnson et al., in 
submission), control mice were not incorporated into this study.  Once techniques 
have been developed to successfully block elevated levels of TNF-α and IL-1β, a 
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study analyzing the acute and chronic phase development of Theiler’s virus 
infection involving SDR and control mice will be conducted. 
In the TNF-α experiment, the successful application of SDR is indicated by 
the development of splenomegaly (enlarged spleens highly correlated with SDR), 
in both antibody and vehicle treated mice, and GCR, a hallmark of SDR.  
Spleens of antibody and vehicle mice were larger than spleens of mice not 
experiencing SDR (based on previous spleen weights of control mice in our 
laboratory).  A GCR assay performed on the spleens of TNF-α mice indicated 
that resistance of macrophages to GC was present.  The development of GCR in 
mice receiving antibody to TNF-α or vehicle treatment implies that this cytokine is 
not necessary for the development of the insensitivity to this hormone.  The 
inability of an ELISA to detect levels of TNF-α in the CNS or periphery indicates 
the need to develop more sensitive assays to the cytokine, as stated previously.  
In addition to an RT-PCR or RNase assay, blood plasma, instead of blood sera, 
could be used in the ELISA.   
The IL-1β experiment also indicated that SDR was successfully applied.  
The spleens of IL-1β mice were enlarged (above the average weight of spleens 
from previous control mice in our laboratory).  A GCR assay was not performed 
on IL-1β mice due to data provided by the IL-6 and TNF-α studies that indicated 
the development of GCR in the presence of neutralizing antibodies.  Our 
laboratory also wanted to ensure successful blockage of IL-1β before spending 
our resources on a GCR assay.  An ELISA detected elevations in cytokine levels 
in the CNS and periphery of IL-1β mice receiving antibody treatment.  However, 
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the antagonism of IL-1β in the CNS was only partially effective, indicated by the 
low, but insignificant, p-value obtained (p=.1).  Unlike the partial antagonism 
achieved in the CNS, no blockage of IL-1β was detected in the periphery. 
Adjustments to the techniques used in the TNF-α and IL-1β studies are 
necessary.  Once levels of TNF-α are successfully detected, an adequate 
blocking dose can be found.  Future studies will then be able to explore a dose 
response curve for antibodies to TNF-α.  Because levels of IL-1β were marginally 
blocked in the CNS, a dose-response curve needs to be investigated.  The 
selective homogenization of certain portions of the brain could also be employed, 
due to the uneven production of cytokines in different regions of the brain.  This 
could provide better insight into the ability of polyclonal antibodies to successfully 
antagonize IL-1β levels in the periphery. 
Once methods to antagonize pro-inflammatory cytokines TNF-α and IL-1β 
have been developed, future studies in our laboratory will further explore the 
roles of these cytokines in mediating the adverse effects of SDR on the 
development of neurodegenerative diseases, such as rheumatoid arthritis and 
MS.  These studies will seek to investigate the necessity and sufficiency of pro-
inflammatory cytokines (TNF-α and IL-1β) in the development of the adverse 
effects of Theiler’s virus infection.  These studies could provide insight into 
possible human interventions.  MS patients, for example, seem to experience 
stressful life events prior to the onset of symptoms.  In addition, GCR in MS 
patients has been previously associated with chronic stress (Mohr et al., 2005).  
These studies and others show the complex interactions of social stressors and 
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the immune system.  Ultimately, our goal is to understand the mechanisms by 
which social stressors alter immune function. 
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